This work is licensed under the Creative Commons Attribution 4.0 International License.
Emile JF, Abla Q, Fraitag S, Hornes A, Haroches J, Donandieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE, Charlotte F, Diamond EL, Egeler RM, Fischer A, Herrera JG, Hentler JI, Janku F, Merad M, Picarsic J, Rodriguez-Galindo C, Rollins BJ, Tazi A, Vaddallo R, Weiss LM for the Histiocyte Society. Revised classification ofhistiocytoses and neoplasms of the macrophagr-dendritic cell lineages. Blood 2016 Jun 2;127(22):2672-2681.EmileJFAblaQFraitagSHornesAHarochesJDonandieuJRequena-CaballeroLJordanMBAbdel-WahabOAllenCECharlotteFDiamondELEgelerRMFischerAHerreraJGHentlerJIJankuFMeradMPicarsicJRodriguez-GalindoCRollinsBJTaziAVaddalloRWeissLM for the Histiocyte Society.Revised classification ofhistiocytoses and neoplasms of the macrophagr-dendritic cell lineages2016Jun 2127222672268110.1182/blood-2016-01-690636516100726966089Search in Google Scholar
Haupt R, Minkov M, Astigarraga I, Schäfer E, Nanduri V, Jubran R, Egeler RM, Janka G, Micic D, Rodriguez-Galindo C, Van Gool S, Visser J, Weitzman S, Donadieu J; Euro Histio Network. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013 Feb;60(2):175-178.HauptRMinkovMAstigarragaISchäferENanduriVJubranREgelerRMJankaGMicicDRodriguez-GalindoCVanGool SVisserJWeitzmanSDonadieuJ; Euro Histio Network.Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years2013Feb60217517810.1002/pbc.24367455704223109216Search in Google Scholar
Adam E, Jubran R, Weitzman S. Epidemiology and clinical manifestation of Langerhans cell histiocytosis in children. W: Histiocytic disorders. Abla O, Janka G (red.) 1st ed. Springer, 2018.AdamEJubranRWeitzmanSSpringer201810.1007/978-3-319-59632-7_3Search in Google Scholar
Raciborska A, Rogowska E, Słowińska M. Pacjent z Histiocytozą z komórek Langerhansa. Co ważnego dla Pediatry. Pediatr Dyplom. 2018,3:75-84.RaciborskaARogowskaESłowińskaMPacjent z Histiocytozą z komórek Langerhansa201837584Search in Google Scholar
Heisig A, Sörensen J, Zimmermann SY, Schöning S, Schwabe D, Kvasnicka HM, Schwentner R, Hutter C, Lehrnbecher T. Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature. Oncotarget. 2018 Apr 24;9(31):22236-22240.HeisigASörensenJZimmermannSYSchöningSSchwabeDKvasnickaHMSchwentnerRHutterCLehrnbecherTVemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature2018Apr 24931222362224010.18632/oncotarget.25277595514529774135Search in Google Scholar
Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010 Sep 16;116(11):1919-1923.Badalian-VeryGVergilioJADegarBAMacConaillLEBrandnerBCalicchioMLKuoFCLigonAHStevensonKEKehoeSMGarrawayLAHahnWCMeyersonMFlemingMDRollinsBJ.Recurrent BRAF mutations in Langerhans cell histiocytosis2010Sep 16116111919192310.1182/blood-2010-04-279083317398720519626Search in Google Scholar
Tran G, Huynh TN, Paller AS. Langerhans cell histiocytosia: a neoplastic disorder driven by Ras-ERK pathway mutations. J Am Acad Dermatol. 2018 Mar;78(3):579-590.TranGHuynhTNPallerASLangerhans cell histiocytosia: a neoplastic disorder driven by Ras-ERK pathway mutations2018Mar78357959010.1016/j.jaad.2017.09.02229107340Search in Google Scholar
Rollins BJ. Biology and genomics of LCH and related disorders. W: Histiocytic disorders. Abla O, Janka G (red.) 1st ed. Springer, 2018.RollinsBJSpringer201810.1007/978-3-319-59632-7_2Search in Google Scholar
Rizzo FM, Cives M, Simone V, Silvestris F. New insights into the molecular pathogenesis of langerhans cell histiocytosis. Oncologist. 2014 Feb;19(2):151-163.RizzoFMCivesMSimoneVSilvestrisFNew insights into the molecular pathogenesis of langerhans cell histiocytosis2014Feb19215116310.1634/theoncologist.2013-0341392678924436311Search in Google Scholar
Hutter C, Minkov M. Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies. Immunotargets Ther. 2016 Oct 12;5:81-91.HutterCMinkovMInsights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies2016Oct 125819110.2147/ITT.S91058506685027785447Search in Google Scholar
Haroche J, Cohen-Aubart F, Emile JF, Donadieu J, Amoura Z. Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis. J Am Acad Dermatol. 2015 Jul; 73(1):e29-30.HarocheJCohen-AubartFEmileJFDonadieuJAmouraZVemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis2015Jul731e293010.1016/j.jaad.2014.10.04526089069Search in Google Scholar
Héritier S, Jehanne M, Leverger G, Emile JF, Alvarez JC, Haroche J, Donadieu J. Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. JAMA Oncol. 2015 Sep; 1(6):836-838.HéritierSJehanneMLevergerGEmileJFAlvarezJCHarocheJDonadieuJ.Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis2015Sep1683683810.1001/jamaoncol.2015.073626180941Search in Google Scholar